Evidence supporting the use of: Inosine
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Inosine has been investigated as a potential adjunct therapy for Parkinson’s Disease (PD) due to its ability to elevate serum and cerebrospinal fluid urate levels. Epidemiological studies have observed that higher urate concentrations are associated with a slower rate of PD progression, suggesting a possible neuroprotective effect of urate—likely related to its antioxidant properties. The most notable trial, the SURE-PD (Safety of Urate Elevation in Parkinson’s Disease) and subsequent SURE-PD3 studies, examined whether inosine supplementation could safely elevate urate levels and slow clinical decline in early PD.

The SURE-PD3, a multicenter, randomized, placebo-controlled phase 3 trial, tested inosine in people with early PD but found no evidence that inosine slowed disease progression compared to placebo. While inosine effectively raised urate levels, it did not improve clinical outcomes or provide neuroprotection. Additionally, there were safety concerns, such as an increased risk of kidney stones. Thus, although the rationale for urate elevation was grounded in observational data and some mechanistic plausibility, randomized clinical trial evidence does not support the use of inosine for treating or modifying the course of Parkinson’s Disease.

In summary, while the use of inosine for PD is based on a scientific hypothesis and has been the subject of clinical trials, current evidence does not validate its efficacy. The strength of evidence supporting its use is weak (rated 2/5), and routine clinical use is not justified.

More about inosine
More about Parkinson's Disease

Other health conditions supported by inosine

Parkinson's Disease

Products containing inosine

We currently have no products on Vitabase that contain this ingredient.